EMA consults on risk-based auditing of pharmacovigilance systems, communicating safety info
This article was originally published in Scrip
Executive Summary
The European Medicines Agency is seeking feedback on two draft modules to be included in its good pharmacovigilance practice guideline (GVP). The latest modules pertain to pharmacovigilance audits and communication of safety information.
You may also be interested in...
UK Warns Against Printing Out EHRs For Clinical Trial Monitors
New UK guidance explains how clinical trial sponsors and investigator sites can ensure that trial monitors securely process data in electronic health record systems that do not have a restricted access functionality.
Swissmedic Clears Up Confusion Over Validity Of GMP Certificates
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
How Merck Plans To Protect Commercial Info Under EU Clinical Trial Rules
In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.
Need a specific report? 1000+ reports available
Buy Reports